Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).
1. A compound of the Formula
wherein:
each R 1 is independently —H;
each R 2 is independently —H, —C 1 -C 6 alkyl, or —C(O)—C 1 -C 6 alkyl, or both R 2 groups combine to form —C(O)— or —C(R a )(R a )—, wherein each R a is independently —H, —C 1 -C 6 alkyl or phenyl;
R 3 is —H; and
Z is —C 1 -C 10 alkyl;
or a pharmaceutically acceptable salt, solvate or hydrate thereof.
2. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate or hydrate thereof.
3. A method for making Compound (L):
comprising reacting a compound having the structure
with a hydroxide ion, under conditions sufficient to produce Compound (L).
4. A composition comprising an effective amount of the compound of claim 1 and at least one of a physiologically acceptable carrier or vehicle, and a drug.
5. The composition of claim 4 wherein the drug is comprised of a member of the group selected from a tubulin-binding drug, a cytotoxic agent drug and an anticancer agent drug and combinations and mixtures thereof.
6. The composition of claim 5 , wherein the tubulin-binding drug is selected from the group consisting of allocolchicine, amphethinile, chelidonine, colchicide, colchicine, combrestatin A1, combretastin A4, combretastain A4 phosphate, combrestatin 3, combrestatin 4, cryptophycin, curacin A, deo-dolastatin 10, desoxyepothilone A, desoxyepothilone B, dihydroxy-pentamethoxyflananone, docetaxel, dolastatin 10, dolastatin 15, epidophyllotoxin, epothilone A, epothilone B, epothilone C, epothilone D, etoposide, 9,10-dehydro-desoxyepothilone B, iso-oxazole-dehydelone, fludelone, iso-oxazole-fludelone, griseofulvin, halichondrin B, isocolchicine, lavendustin A, methyl-3,5-diiodo-4-(4′-methoxyphenoxy)benzoate, N-acetylcolchinol, N-acetylcolchinol-O-phosphate, N42-[(4-hydroxyphenypamino]-3-pyridyl]-4-methoxybenzenesulfonamide, nocodazole, paclitaxel, phenstatin, phenylhistin, piceid, podophyllotoxin, resveratrol, rhizoxin, sanguinarine, spongistatin 1, steganacin, paclitaxel, teniposide, thiocolchicine, vincristine, vinblastine, welwistatin, (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine, (Z)-3,5,4′-trimethoxystilbene (R 3 ), 2-aryl-1,8-naphthyridin-4(1H)-one, 2-(4′-methoxyphenyl)-3-(3′,4′,5′-trimethoxybenzoyl)-6-methoxybenzo[b]thiophene, 2-methoxy estradiol, 2-strylquinazolin-4(3H)-one, 5,6-dihydroindolo(2,1-a)isoquinoline, or 10-deacetylbaccatin III and wherein the anticancer agent drug is selected from the group consisting of 5-fluorouracil, cyclophosphamide, isodehydelone, fludelone, iso-oxazole-fludelone, or paclitaxel.
7. A composition comprising an effective amount of a compound of claim 2 and at least one of a physiologically acceptable carrier or vehicle, and a drug.
8. The composition of claim 7 , wherein the drug is comprised of a member of the group selected from a tubulin-binding drug, a cytotoxic agent drug and an anticancer agent drug and combinations and mixtures thereof.
9. The composition of claim 8 , wherein the tubulin-binding drug is selected from the group consisting of allocolchicine, amphethinile, chelidonine, colchicide, colchicine, combrestatin A1, combretastin A4, combretastain A4 phosphate, combrestatin 3, combrestatin 4, cryptophycin, curacin A, deo-dolastatin 10, desoxyepothilone A, desoxyepothilone B, dihydroxy-pentamethoxyflananone, docetaxel, dolastatin 10, dolastatin 15, epidophyllotoxin, epothilone A, epothilone B, epothilone C, epothilone D, etoposide, 9,10-dehydro-desoxyepothilone B, iso-oxazole-dehydelone, fludelone, iso-oxazole-fludelone, griseofulvin, halichondrin B, isocolchicine, lavendustin A, methyl-3,5-diiodo-4-(4′-methoxyphenoxy)benzoate, N-acetylcolchinol, N-acetylcolchinol-O-phosphate, N-[2-[(4-hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide, nocodazole, paclitaxel, phenstatin, phenylhistin, piceid, podophyllotoxin, resveratrol, rhizoxin, sanguinarine, spongistatin 1, steganacin, paclitaxel, teniposide, thiocolchicine, vincristine, vinblastine, welwistatin, (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine, (Z)-3,5,4′-trimethoxystilbene (R3), 2-aryl-1,8-naphthyridin-4(1H)-one, 2-(4′-methoxyphenyl)-3-(3′,4′,5′-trimethoxybenzoyl)-6-methoxybenzo[b]thiophene, 2-methoxy estradiol, 2-strylquinazolin-4(3H)-one, 5,6-dihydroindolo(2,1-a)isoquinoline, or 10-deacetylbaccatin III and wherein the anticancer agent drug is selected from the group consisting of 5-fluorouracil, cyclophosphamide, isodehydelone, fludelone, iso-oxazole-fludelone, or paclitaxel.
10. A composition comprising an effective amount of a compound selected from Formulas L and L′:
and at least one of a physiologically acceptable carrier or vehicle, and a drug.
11. The composition of claim 10 wherein the drug is comprised of a member of the group selected from a tubulin-binding drug, a cytotoxic agent drug and an anticancer agent drug and combinations and mixtures thereof.
12. A method for inducing a chemoprotective phase II enzyme in a subject; inducing expression of a chemoprotective phase II enzyme in a subject; inducing enzymatic activity of a chemoprotective phase II enzyme; reducing the side effects of a drug; reducing body weight loss side effects of a drug; reducing the side effects of a cancer therapeutic drug or cancer treatment; reducing the side effects of a tubulin-binding drug; reducing a toxic effect of a toxic agent wherein a subject has been or is currently exposed to a drug and is also exposed to the toxic agent; reducing a cytotoxic effect of a cytotoxic agent; reducing a toxic effect of a toxic agent comprising a chemotherapeutic agent; reducing a neurotoxic toxic effect of a neutrotoxic toxic agent; reducing peripheral neuropathy; inducing antioxidant phase-2 enzymes in vivo; comprising administering to an animal or human subject in need thereof an effective amount of a compound of claim 1 .
13. The method of claim 12 , wherein the chemoprotective phase II enzyme is at least one of a quinone reductase, AKR1C, AKR1C2, AKR1C3, heme oxygenase-1 (HO-1), quinone reductase, NAD(P)H:quinone reductase (NQO1), superoxide dismutase, glutathione peroxidase, nuclear erythroid-2 related factor 2 (Nrf2), or UDP-glucuronosyl transferase 2B7, or a combination or selection thereof.
14. The method of claim 12 , wherein the chemoprotective phase II enzyme is induced by the compound binding to an Antioxidant Response Element (ARE).
15. A method for inducing a chemoprotective phase II enzyme in a subject; inducing expression of a chemoprotective phase II enzyme in a subject;
inducing enzymatic activity of a chemoprotective phase II enzyme; reducing the side effects of a drug; reducing body weight loss side effects of a drug; reducing the side effects of a cancer therapeutic drug or cancer treatment; reducing the side effects of a tubulin-binding drug; reducing a toxic effect of a toxic agent wherein a subject has been or is currently exposed to a drug and is also exposed to the toxic agent; reducing a cytotoxic effect of a cytotoxic agent; reducing a toxic effect of a toxic agent comprising a chemotherapeutic agent; reducing a neurotoxic toxic effect of a neutrotoxic toxic agent; reducing peripheral neuropathy; inducing antioxidant phase-2 enzymes in vivo; comprising administering to an animal or human subject in need thereof an effective amount of the compound of claim 2 .
16. A method for, treating lung cancer breast cancer, colorectal cancer, prostate cancer, a leukemia, a lymphoma, non-Hodgkin's lymphoma, skin cancer, a brain cancer, a cancer of the central nervous system, ovarian cancer, uterine cancer, stomach cancer, pancreatic cancer, esophageal cancer, kidney cancer, liver cancer, or a head and neck cancer comprising administering to an animal or human subject in need thereof an effective amount of a composition of claim 4 .
17. The method of claim 12 , wherein the cancer treatment having side effects is radiation therapy.
18. The method of claim 15 , wherein the cancer treatment having side effects is radiation treatment.